Dapoxetine orally disintegrating tablet composition and preparation method thereof
By adding magnesium oxide and citric acid to dapoxetine oral disintegration tablets and combining appropriate auxiliary materials and processes, the bitter and irritating stimulation and process complexity of the drug disintegration process is solved, and rapid disintegration and Improves taste, improves user experience and process operability.
Patent Information
- Application Number
- CN202410686377.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-30
- Filing Date
- 2024-05-30
- Publication Date
- 2024-12-03
AI Technical Summary
The existing dapoxetine oral disintegration tablets have a bitter and irritating feeling during the disintegration process, and the process is complex and not practical, which affects the user experience.
Optimize the pharmaceutical composition by adding magnesium oxide and citric acid to dapoxetine oral disintegration tablets and combining appropriate fillers, disintegrants, flavoring agents and lubricants, using direct mixing tableting or other preparation processes. The proportion and process flow of the drug can improve the disintegration speed and taste.
The rapid disintegration of dapoxetine oral disintegration tablets has been achieved, which has improved the bitter and irritating feeling of the drug, improved the user's use compliance, and reduced the process complexity and risk of organic solvent residue.
Smart Images

Figure BDA0004867115310000031 
Figure BDA0004867115310000041 
Figure BDA0004867115310000042
Abstract
Description
Technical Field
[0001] The present invention relates to the field of pharmaceutical compositions, and in particular to daboxetine orally disintegrating tablets and a preparation method thereof. Background Art
[0002] Dapoxetine hydrochloride was originally developed by Eli Lilly Pharmaceuticals. The drug was first approved for marketing in Finland and Sweden for the treatment of premature ejaculation. It is suitable for men aged 18-64 years old. Its trade name is PRILIGY.
[0003] Dapoxetine hydrochloride is a selective serotonin reuptake inhibitor. Currently, the product marketed domestically and internationally is a film-coated tablet (Priligy), which is suitable for the treatment of premature ejaculation (PE) in adult males aged 18 to 64. The drug is absorbed quickly and can quickly reach an effective blood concentration. Dapoxetine is rapidly absorbed, and the maximum plasma concentration (Cmax) occurs about 1-2 hours after tablet ingestion. The absolute bioavailability is 42% (range 15-76%), the half-life is short, and it is metabolized through multiple pathways.
[0004] Orally disintegrating tablets (orally disintegrating tablets) are tablets that can be quickly dissolved in saliva or quickly disintegrated in the mouth. Patients do not need to use water or chew. The drug is placed in the mouth, and after it quickly dissolves or disintegrates with saliva, it takes effect after entering the digestive system with the voluntary and involuntary swallowing action of the user. It has the advantages of easy use, fast absorption, and high bioavailability. Patent CN201510827956.3 discloses a preparation process in which dapoxetine hydrochloride is prepared into a solid dispersion and then directly compressed with excipients. Although the tablets prepared by this process dissolve quickly and can be released quickly, organic solvents are used in the process, and problems such as organic solvent residues need to be paid attention to in the later stage. The process is complicated and the actual operability is not high. Patent CN201410049016.1 solves the problem of slow disintegration by adding a certain amount of inactive substance sodium dodecyl sulfate to the disintegrant, but it cannot solve the problem of the taste of the product. At the same time, taste is one of the important parameters of orally disintegrating tablets. Summary of the invention
[0005] In view of the many deficiencies in the prior art, the present invention provides a dapoxetine orodisintegrating tablet composition and a preparation method thereof, which can achieve rapid disintegration in the oral cavity, and unexpectedly found that the bitter and numbing irritation of the drug can be greatly improved after adding magnesium oxide and citric acid, thereby better improving the compliance of the user population.
[0006] In some embodiments, the present invention provides a dapoxetine orally disintegrating tablet composition, wherein the dapoxetine composition comprises dapoxetine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient, wherein the pharmaceutical excipient comprises a filler, a disintegrant, a flavoring agent and a lubricant, and comprises a metal compound and an organic acid, wherein the metal compound is selected from one or more of metal oxides and metal hydroxides. In some embodiments, in the pharmaceutical composition, the pharmaceutically acceptable salt of dapoxetine is a hydrochloride.
[0007] In some embodiments, in the pharmaceutical composition, the mass ratio of dapoxetine or a pharmaceutically acceptable salt thereof to the metal compound is 1:3 to 10:1, preferably 1:2 to 8:1.
[0008] In some embodiments, in the pharmaceutical composition, the mass ratio of dapoxetine or a pharmaceutically acceptable salt thereof to the organic acid is 1:2 to 12:1, preferably 1:1 to 10:1.
[0009] In some embodiments, in the pharmaceutical composition, the metal oxide is selected from magnesium oxide, and the metal hydroxide is selected from calcium hydroxide.
[0010] In some embodiments, in the pharmaceutical composition, the organic acid is selected from one or more of citric acid, tartaric acid, and malic acid.
[0011] In some embodiments, in the pharmaceutical composition, the filler comprises one or more of mannitol, lactose, microcrystalline cellulose, corn starch, starch hydrolyzed oligosaccharides, polyvinyl acetate, acrylic resin, glyceryl behenate, and stearic acid.
[0012] In some embodiments, in the pharmaceutical composition, the disintegrant comprises one or more of low-substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose, and cross-linked polyvinylpyrrolidone, preferably one or a combination of cross-linked sodium carboxymethyl cellulose and cross-linked polyvinylpyrrolidone.
[0013] In some embodiments, in the pharmaceutical composition, the weight percentage of the disintegrant is 3% to 30%, preferably 5% to 20%, and more preferably 8% to 15%.
[0014] In some embodiments, in the pharmaceutical composition, the flavoring agent comprises sweeteners, flavors, citric acid and magnesium oxide.
[0015] In some embodiments, in the pharmaceutical composition, the sweetener is one or more of sucrose, glucose, cyclamate, stevioside, dextrin, saccharin sodium, xylose, aspartame, sucralose, and acesulfame potassium, preferably one or more of sucralose, aspartame, and dextrin.
[0016] In some embodiments, in the pharmaceutical composition, the weight percentage of the sweetener is 0.1%-5%, preferably 1%-3%.
[0017] In some embodiments, in the pharmaceutical composition, the lubricant comprises one or more of magnesium stearate, talc, micro-powdered silica gel, and sodium stearyl fumarate.
[0018] In some embodiments, in the pharmaceutical composition, the weight percentage of the lubricant is 0.2%-5%, preferably 0.5%-3%.
[0019] In some embodiments, the preparation process includes one or more of a direct mixing tableting process, a powder coating followed by tableting process, a melt granulation followed by tableting process, and a wet granulation followed by tableting process.
[0020] In some embodiments, the preparation process includes: wet granulating an acceptable salt of dapoxetine with a portion of a filler and a portion of a disintegrant, adding the remaining amount of the filler, disintegrant and flavoring agent to mix evenly, and finally adding a lubricant to mix and then tableting.
[0021] In some embodiments, the preparation process includes: combining an acceptable salt of dapoxetine with a resin to form a resin complex, adding other auxiliary materials and performing tableting.
[0022] In some embodiments, the preparation process includes: coating the raw materials or granulating the raw materials and then coating them, adding other auxiliary materials or other auxiliary materials after granulation and tableting.
[0023] In some embodiments, the preparation process includes: pre-treating the raw materials and auxiliary materials, and then mixing and tableting.
[0024] In some embodiments, the preparation process includes the steps of melting a low melting point matrix, adding an acceptable salt of dapoxetine and mixing evenly, and adding other auxiliary materials for tableting. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Unless otherwise defined herein, scientific and technical terms related to the present invention shall have the meanings understood by those of ordinary skill in the art. DETAILED DESCRIPTION
[0026] The present invention will be further described below in conjunction with specific examples, and the advantages and features of the present invention will become clearer as the description proceeds. Where specific conditions are not specified in the examples, conventional conditions or conditions recommended by the manufacturer are used. Where the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0027] The embodiments of the present invention are only exemplary and do not constitute any limitation to the scope of the present invention. It should be understood by those skilled in the art that the details and forms of the technical solution of the present invention may be modified or replaced without departing from the spirit and scope of the present invention, but these modifications and replacements all fall within the scope of protection of the present invention.
[0028] Example 1
[0029] Table 1
[0030] Prescription composition Dosage (mg / tablet) Dapoxetine Hydrochloride 30 Mannitol 65 Corn starch 60 Croscarmellose Sodium 15 Povidone K30 3 Sucralose 1 Magnesium Stearate 1 Tablet weight 175
[0031] Preparation method: Pass the raw materials and excipients through an 80-mesh sieve, mix mannitol, corn starch, cross-linked sodium carboxymethyl cellulose, povidone K30, and sucralose evenly, add the prescribed amount of dapoxetine hydrochloride and continue to mix evenly, add magnesium stearate and mix evenly, and tablet the tablets within a tablet weight range of ±7.5% to obtain the sample.
[0032] Example 2
[0033] Table 2
[0034] Prescription composition Dosage (mg / tablet) Dapoxetine Hydrochloride 30 Mannitol 60 Starch hydrolyzed oligosaccharides 42 Microcrystalline Cellulose 10 Croscarmellose Sodium 20 Citric Acid 10 Sucralose 1 Magnesium Stearate 1 Mint powder flavor 1 Tablet weight 175
[0035] Preparation method: Pass the raw materials through an 80-mesh sieve, mix mannitol, starch hydrolyzed oligosaccharides, microcrystalline cellulose, cross-linked sodium carboxymethyl cellulose, and sucralose evenly, add the prescribed amount of dapoxetine hydrochloride and continue to mix evenly, add magnesium stearate and mix evenly, and tablet the tablets within a tablet weight range of ±7.5% to obtain the sample.
[0036] Example 3
[0037] Table 3
[0038]
[0039] Preparation method: The raw materials and auxiliary materials are passed through an 80-mesh sieve, the wet-process raw materials and auxiliary materials are mixed evenly, 3% hydroxypropyl methylcellulose is added for wet granulation, drying, and granulation. The granules are further added with additional auxiliary materials except the converted magnesium stearate and mixed evenly, and finally the magnesium stearate is mixed evenly, and tablets are pressed according to the tablet weight range of ±7.5% to obtain the sample.
[0040] Example 4
[0041] Table 4
[0042]
[0043] Preparation method:
[0044] (1) Dapoxetine hydrochloride and acrylic resin Eudragit EPO are completely dissolved in anhydrous ethanol at a ratio of 1:1, and then dried under reduced pressure to obtain a dapoxetine acrylic resin complex, which is crushed and passed through an 80-mesh sieve.
[0045] (2) All excipients were sieved through an 80-mesh sieve, dapoxetine acrylic resin complex, light magnesium oxide, citric acid, mannitol, cross-linked sodium carboxymethyl cellulose, povidone, sucralose, aspartame, and mint powder flavor were mixed evenly, magnesium stearate was added and mixed evenly, and tablets were pressed into tablets within a tablet weight range of ±7.5% to prepare samples.
[0046] Example 5
[0047] Table 5
[0048]
[0049] Preparation method:
[0050] (1) Dissolve the acrylic resin Eudragit EPO in a 90% ethanol aqueous solution, add talcum powder in a ratio of 1:1 and stir evenly to obtain a coating solution, and use the coating solution to powder coat dapoxetine hydrochloride.
[0051] (2) All excipients were passed through an 80-mesh sieve, dapoxetine acrylic resin coating, calcium hydroxide, tartaric acid, mannitol, starch hydrolyzed oligosaccharide, cross-linked polyvinylpyrrolidone, polyvinylpyrrolidone, sucralose, aspartame, and mint powder flavor were mixed evenly, magnesium stearate was added and mixed evenly, and tablets were pressed according to a tablet weight range of ±7.5% to prepare a sample.
[0052] Example 6
[0053] Table 6
[0054]
[0055] Preparation method:
[0056] (1) Dissolve the acrylic resin Eudragit EPO in a 90% ethanol aqueous solution, add talcum powder in a ratio of 1:1 and stir evenly to obtain a coating solution, and use the coating solution to powder-coat a prescribed amount of dapoxetine hydrochloride and a prescribed amount of mannitol to obtain taste-masked particles.
[0057] (2) Granulating other excipients to obtain drug-free particles.
[0058] (3) The above-mentioned drug-containing granules and drug-free granules, light magnesium oxide, malic acid, sucralose, aspartame, and mint powder flavor were mixed evenly, and finally magnesium stearate was added and mixed evenly, and tablets were pressed into tablets within a tablet weight range of ±7.5% to prepare samples.
[0059] Example 7
[0060] Table 7
[0061] Prescription composition Dosage (mg / tablet) Dapoxetine Hydrochloride 30 Light magnesium oxide 20 Anhydrous citric acid 10 lactose 40 Microcrystalline Cellulose 35 Croscarmellose Sodium 15 Povidone K30 3 Polyvinyl acetate 10 Acesulfame K 1.25 talcum powder 3 Silicon dioxide 1.75 dextrin 4 Mint powder flavor 2 Tablet weight 175mg
[0062] All auxiliary materials were passed through an 80-mesh sieve, and the raw and auxiliary materials except magnesium stearate, acesulfame potassium, and mint powder flavor were mixed evenly. Melt granulation was adopted, and finally magnesium stearate was added and mixed evenly. The samples were prepared by tableting according to the tablet weight range of ±7.5%.
[0063] Test Example 1
[0064] Disintegration time test The above Examples 1-7 were measured according to the disintegration time test method in the Chinese Pharmacopoeia (2020 Edition).
[0065] Friability Test The above Examples 1-7 were measured according to the tablet friability test method of 0923 of the Chinese Pharmacopoeia "2020 Edition".
[0066] Example Disintegration time friability 1 50S qualified 2 42S qualified 3 45-50S qualified 4 42S qualified 5 36S qualified 6 30S qualified 7 52S qualified
[0067] Test Example 2
[0068] Taste Evaluation Ten volunteers were randomly selected to evaluate the taste of Examples 1-10, and the evaluation indicators included grittiness, bitterness, and pungent taste, and statistics were performed.
[0069] Taste test standard: Before the formal taste evaluation, each volunteer rinsed his mouth with no less than 100 ml of water, then put each example tablet into his mouth and recorded the taste. After the trial, he continued to rinse his mouth with no less than 100 ml of water, and conducted the taste test of the next product 2 hours later.
[0070] Taste evaluation (n=10)
[0071]
[0072] In summary, the orodisintegrating tablets of dapoxetine of the present invention can solve the bitterness and spicy and numbing stimulation of the raw materials. In addition, the orodisintegrating tablets have no obvious grittiness and bad taste, which greatly improves the compliance of the product.
Claims
1. A dapoxetine orally disintegrating tablet pharmaceutical composition, comprising dapoxetine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient, wherein the excipient comprises a filler, a disintegrant, a flavoring agent and a lubricant, wherein the flavoring agent comprises a metal compound and an organic acid, wherein the metal compound is selected from one or more of metal oxides and metal hydroxides, and the pharmaceutically acceptable salt of dapoxetine is a hydrochloride.
2. The pharmaceutical composition according to claim 1, wherein The mass ratio of dapoxetine or a pharmaceutically acceptable salt thereof to the metal compound is 1:3 to 10:1, preferably 1:2 to 8:
1.
3. The pharmaceutical composition according to claim 1, wherein The mass ratio of dapoxetine or its pharmaceutically acceptable salt to the organic acid is 1:2 to 12:1, preferably 1:1 to 10:
1.
4. The pharmaceutical composition according to claim 1, wherein The metal oxide is selected from magnesium oxide, and the metal hydroxide is selected from calcium hydroxide.
5. The pharmaceutical composition according to claim 1, wherein The organic acid is selected from one or more of citric acid, tartaric acid and malic acid.
6. The pharmaceutical composition according to claim 1, wherein The filler is selected from one or more of mannitol, lactose, microcrystalline cellulose, corn starch, starch hydrolyzed oligosaccharides, polyvinyl acetate, acrylic resin, glyceryl behenate, and stearic acid.
7. The pharmaceutical composition according to claim 1, wherein The disintegrant is selected from one or more of low-substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose, and cross-linked polyvinylpyrrolidone, preferably one or a combination of cross-linked sodium carboxymethyl cellulose and cross-linked polyvinylpyrrolidone.
8. The pharmaceutical composition according to claim 1, wherein The weight percentage of the disintegrant is 3% to 30%, preferably 5% to 20%, and more preferably 8% to 15%.
9. The pharmaceutical composition according to any one of claims 1 to 8, wherein The flavoring agent comprises sweetener, flavor, citric acid and magnesium oxide.
10. The pharmaceutical composition according to claim 9, wherein The sweetener is one or more of sucrose, glucose, sodium cyclamate, stevioside, dextrin, sodium saccharin, xylose, aspartame, sucralose, and acesulfame potassium, preferably one or more of sucralose, aspartame, and dextrin.
11. The pharmaceutical composition according to any one of claims 1 to 10, wherein The weight percentage of the sweetener is 0.1%-5%, preferably 1%-3%.
12. The pharmaceutical composition according to claim 1, wherein The lubricant comprises one or more of magnesium stearate, talcum powder, micro powder silica gel, and sodium stearyl fumarate.
13. The pharmaceutical composition according to claim 12, wherein The weight percentage of the lubricant is 0.2%-5%, preferably 0.5%-3%.
14. The pharmaceutical composition according to any one of claims 1 to 13, characterized in that The preparation process of the pharmaceutical composition includes one or more of a direct mixing tableting process, a powder coating followed by tableting process, a melt granulation followed by tableting process, and a wet granulation followed by tableting process.
Citation Information
Patent Citations
Dapoxetine tablets and preparation method thereof
CN103735525A
A type of dapoxetine hydrochloride tablet
CN105232503B
